Xiaonan Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xiaonan Li has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Ribai Yan
School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
1 shared publication - Xin-Shan Ye
State Key Laboratory of Natural and Biomimetic Drugs School of Pharmaceutical Sciences and Chemical Biology Center Peking University Beijing China
1 shared publication - Yuheng Liu
Hebei Medical University
1 shared publication
Latest Publications
- Open Access
Design, Synthesis, and Bioassay of 2′-Modified Kanamycin A
Chemical modification of old drugs is an important way to obtain new ones, and it has been widely used in developing new aminoglycoside antibiotics. However, many of the previous modifying strategies seem arbitrary for their lack of support from structural biological detail. In this paper, based on the structural information of aminoglycoside and its drug target, we firstly analyzed the reason that some 2′-N-acetylated products of aminoglycosides caused by aminoglycoside-modifying enzyme AAC(2′) can partially retain activity, and then we designed, synthesized, and evaluated a series of 2′-modified kanamycin A derivatives. Bioassay results showed our modifying strategy was feasible. Our study provided valuable structure–activity relationship information, which would help researchers to develop new aminoglycoside antibiotics more effectively.
Open AccessDesign, Synthesis, and Bioassay of 2′-Modified Kanamycin A
Chemical modification of old drugs is an important way to obtain new ones, and it has been widely used in developing new aminoglycoside antibiotics. However, many of the previous modifying strategies seem arbitrary for their lack of support from structural biological detail. In this paper, based on the structural information of aminoglycoside and its drug target, we firstly analyzed the reason that some 2′-N-acetylated products of aminoglycosides caused by aminoglycoside-modifying enzyme AAC(2′) can partially retain activity, and then we designed, synthesized, and evaluated a series of 2′-modified kanamycin A derivatives. Bioassay results showed our modifying strategy was feasible. Our study provided valuable structure–activity relationship information, which would help researchers to develop new aminoglycoside antibiotics more effectively.